Advertisement

The cytoskeleton in Alzheimer disease

  • R. D. Terry
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 53)

Summary

The strongest physical correlate with the severity of dementia in Alzheimer’s disease and its most rational cause are the loss of neocortical and hippocampal synapses. Evidence, showing that β-amyloid causes that loss is weak despite the popularity of that hypothesis. Other changes can better explain that damaging phenomenon. Axonal terminals are dependent on axoplasmic flow, and that function requires intact microtubules and the motor proteins kinesin, dynein and dynamin.

It has been known since the earliest electron microscopic studies of AD that neuronal microtubules are lessened in number. Tubules are normally in equilibrium with unpolymerized tubulin, and the stability of the formed elements is dependent on normal binding of tau to the tubule. But, as is well known, tau is abnormally hyperphosphorylated in AD leading to tangle formation and to dissolution of the tubules. Tangles are insufficient in number to account for the cortical loss of neurons and synapses, but hyperphosphorylated tau in the unpolymerized pre-tangle state undoubtedly plays a role. Abnormalities in the motor proteins are now being investigated (some have already been found) and these too would contribute to the loss of synapses in AD by way diminished axoplasmic flow.

Most investigators of Alzheimer disease (AD) seem confident that the cause of the clinical symptoms is the deposition of amyloid. Since the original isolation and sequencing of this specific peptide by Glenner and Wong (1984), about 3,000 papers have been published concerning it. Such a torrent of information is hard to resist, but there are a number of flaws in the argument that this amyloid is the direct cause of the dementia. Among them is the fact that amyloid inoculated into the brain of the monkey does not induce the Alzheimer-like changes (Podlisny et aI., 1993). A cognitively normal elderly human may have a high concentration of cortical amyloid. There is only poor correlation between the amount of amyloid in the human brain and the severity of the disease (Arriagada et aI., 1992), except in an area such as the entorhinal region (Cummings et aI., 1995) where plaques are clearly a secondary feature. Since the amyloid burden does not correlate with the severity of the disease, one must ask whether pharmacologic reduction of that burden will be clinically useful.

A number of other pathogenic theories have arisen including abnormal calcium influx in neurons (Mattson et a1., 1992), excitotoxic neuronal damage (Cowburn et a1., 1988), abnormal oxidative stress (Bea1 et a1., 1994), physiologic (corticosteroida1) stress (Gould et a1., 1991), and inflammation (McGeer et a1., 1994). There is indeed evidence for each of these possibilities, but none is very strong, at least in terms of primary causation.

A very strong correlate with the clinical severity is synaptic loss in neocortex (Scheff et a1., 1990; Terry et a1., 1991) and hippocampus (Sze et a1., 1997). The loss of synapses causes disconnection (Hof et a1., 1994) among the many functional parts of the brain, and so this is a biologically rational cause of dementia. It is important to realize that a neuron in the central nervous system can lose many of its axonal terminals but survive as an apparently intact soma. This fact explains why cell counts correlate so poorly with function in some degenerative diseases, and how there is greater synaptic loss than neuronal loss in the Alzheimer cortex (Scheff et a1., 1990; Terry et a1., 1991). It also might provide an optimistic view that the synaptic terminals might regenerate given the appropriate stimuli and circumstances. The question then is what causes the loss of synapses, and this writer would have it that synapses die and neurites become dystrophic largely because of abnormal and deficient axoplasmic flow (Suzuki et a1., 1967). Techniques to measure this function in the human are not yet available.

Axop1asmic flow is that essential neural mechanism by which substrates and organelles are moved from the cell body out through both axons and dendrites to their endings, and by which other products are returned from terminals to the cell body. Essential to this process are intact microtubu1es as is proven by the fact that dissolution of microtubu1es (as by colchicine) arrests the process. The protein kinesin provides the motive force for rapid transport along the tubules in the anterograde direction (Vale et a1., 1985), while dynein is the motor for retrograde movement (Paschal et a1., 1987). Both motor proteins gain energy by hydrolyzing ATP, and both must act along intact micro tubules (Fig. 1).

Electron microscopic studies of cortical biopsies performed more than 30 years ago first demonstrated a paucity of microtubu1es in the neurons of AD (Terry et al., 1964). This is true of cells both with and without tangles. Microtubules are in equilibrium with their component monomers alpha and beta tubu1in, so that total tubulin might be normal in a cell although polymerized functional tubules are diminished. In such a case, axop1asmic flow would be deficient.

The effects of synaptic loss, itself due to deficient axop1asmic flow, are multiple. First, there will be disconnection between the several coordinated parts of the brain and thus dementia (Hof et al., 1994). Second, the degenerative synapses will elicit microglial activation, and their cytokines cause further damage (McGeer et al., 1994). Third, the neuron will receive less trophic factor from the target areas since the terminals are not available to pick it up and the retrograde axop1asmic flow is inadequate to transport the factors back to the cell body. Therefore, the soma will ultimately die by way of apoptosis (Cotman et a1., 1994) secondary to its synaptic loss (Fig. 2).

Keywords

Alzheimer Disease Axonal Terminal Synaptic Loss Motor Protein Kinesin Axoplasmic Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arriagada PV, Growden JH, Hedley-White ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer disease. Neurology 42: 631–639PubMedCrossRefGoogle Scholar
  2. Beal MF (1994) Energy, oxidative damage, and Alzheimer’s disease: clues to the underlying puzzle. Neurobiol Aging 15: 171–174CrossRefGoogle Scholar
  3. Corsellis JAN, Bruton CJ, Freeman Browne D (1973) The aftermath of boxing. Psychol Med 3: 270–303PubMedCrossRefGoogle Scholar
  4. Cotman CW, Whitlemore ER, Watt JA, Anderson AJ, Loo DT (1994) Possible role of apoptosis in Alzheimer’s disease. Ann NY Acad Sci 747: 36–49PubMedCrossRefGoogle Scholar
  5. Cowburn R, Hardy J, Roberts P, Briggs R (1988) Presynaptic and post synaptic glutamatergic function in Alzheimer’s disease. Neurosci Lett 86: 109–113PubMedCrossRefGoogle Scholar
  6. Cummings BJ, Cotman CW (1995) Image analysis of beta-amyloid load in Alzheimer’s disease and relation to dementia severity. Lancet 346: 1524–1528PubMedCrossRefGoogle Scholar
  7. Glenner GG, Wong CW (1984) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Comm 122: 1131–1135PubMedCrossRefGoogle Scholar
  8. Gomez-Isla T, Hollister R, et al (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 41: 17–24PubMedCrossRefGoogle Scholar
  9. Gould E, Woolly CS, McEwen BS (1991) Adrenal steroids regulate postnatal development of the rate dentate gyrus. I. Effects of glucocorticoids on cell death. J Comp Neurol 313: 479–485Google Scholar
  10. Graeber MB, Kösel S, Egensperger R, Banati RB, Müller U, Bise K, Hoff P, Möller HJ, Fujisawa K, Mehraein P (1997) Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics 1: 73–80PubMedCrossRefGoogle Scholar
  11. Hanger DP, Brion JP, et al (1991) Tau in Alzheimer’s disease and Down’s syndrome is insoluble and abnormally phosphorylated. Biochem J 275: 99–140PubMedGoogle Scholar
  12. Hof PR, Morrison J (1994) The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. In: Terry RD, Katzman R, Bick K (eds) Alzheimer disease. Raven Press, New York, pp 197–230Google Scholar
  13. Huang DY, Weisgraber KH, et al (1995) APOE3 binding to tau tandem repeat I is abolished by tau serine phosphorylation. Neurosci Lett 192: 209–212PubMedCrossRefGoogle Scholar
  14. Mattson MP, Cheng B (1992) β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12: 376–389PubMedGoogle Scholar
  15. McGeer PL, Walker DG, Akiyama H, et al (1994) Involvement of microglia in Alzheimer’s disease Neuropathol kAppl Neurobiol 20: 191–192Google Scholar
  16. Paschal BM, Shpetner HS, Vallee RB (1987) MAP IC is a microtubule-activated ATPase that translocates microtubules in vitro and has dynein-like properties. J Cell Biol 105: 1273–1282PubMedCrossRefGoogle Scholar
  17. Podlisny MB, Stephenson DT (1993) Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity. Am J Path 142: 17–24PubMedGoogle Scholar
  18. Roses AD, Einstein G, et al (1996) Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Ann NY Acad Sci 777: 146–157PubMedCrossRefGoogle Scholar
  19. Scheff SW, DeKosky ST, Price DA (1990) Quantitative assessment of cortical synaptic density in Alzheimer’s disease. Neurobiol Aging 11: 29–97PubMedCrossRefGoogle Scholar
  20. Stieber A, Mourelatos Z, Gonatas NK (1996) In Alzheimer’s disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic. Am J Path 148: 415–426PubMedGoogle Scholar
  21. Suzuki K, Terry RD (1967) Fine structural localization of acid phosphatase in senile plaques in Alzheimer’s presenile dementia Acta Neuropathol 8: 276–284PubMedCrossRefGoogle Scholar
  22. Sze C-I, Troncoso JC, et al (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56: 933–944PubMedCrossRefGoogle Scholar
  23. Terry RD, Masliah E (1991) Physical basis of cognitive alterations in Alzheimer disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572–580PubMedCrossRefGoogle Scholar
  24. Terry RD, Gonatas NK, Weiss M (1964) Ultrastructural studies in Alzheimer’s presenile dementia. Am J Pathol 44: 269–297PubMedGoogle Scholar
  25. Terry RD, Hansen LA, et al (1987) Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropathol Exp Neurol 46: 262–268PubMedCrossRefGoogle Scholar
  26. Terry RD, Masliah E, Hansen LA (1994) Structural basis of the cognitive alterations in Alzheimer’s disease. In: Terry RD, Katzman R, Bick K (eds) Alzheimer disease. Raven Press, New York, pp 179–196Google Scholar
  27. Vale RD, Reese TS, Sheetz MP (1985) Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. Cell 42: 39–50PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • R. D. Terry
    • 1
  1. 1.Departments of Neurosciences and PathologyUniversity of CaliforniaSan DiegoUSA

Personalised recommendations